The FDA has expanded approval of dupilumab to include children aged 2 to 11 years with chronic spontaneous urticaria who ...

The drug development process is essential to provide an indication of the pharmacotherapeutic potential of an antihistamine and to establish its clinical efficacy. In vitro tests have demonstrated ...

Children under the age of six are at risk of psychiatric and central nervous system side effects, including hyperactivity, aggression and hallucination, and high doses could cause intellectual ...